Key Findings
NTHRYS has reported two significant achievements in the field of immunotherapy for hematological malignancies. First, the company reduced manufacturing costs for dual antigen CAR-T cell scale-up by 40% compared to conventional methods, simultaneously shortening the time to clinical introduction. Second, NTHRYS now provides clinical-grade NK (Natural Killer) cell expansion and cryopreservation service solutions, enabling the supply of off-the-shelf cell products. These technological innovations dramatically improve the accessibility and economic viability of cellular immunotherapies.
Technical / Clinical Details
Dual antigen CAR-T cell therapy is a next-generation cell therapy expected to enhance therapeutic efficacy and prevent immune evasion by cancer cells, addressing antigen diversity—a limitation of single-antigen CAR-T cell therapies. NTHRYS’s developed manufacturing scale-up technology successfully reduced manufacturing costs by 40% by optimizing process efficiency and cutting raw material and labor expenses. This efficiency gain is attributed to multiple factors, including automation in a GMP (Good Manufacturing Practice) environment, optimization of media and cytokines, and the adoption of closed systems.
Furthermore, NTHRYS offers services for large-scale culture and long-term preservation of high-quality NK cells suitable for clinical use. This is supported by optimal culture conditions utilizing cytokines like IL-15 and robust cryopreservation protocols. Unlike autologous CAR-T cell therapies, which require patient-specific cell collection and manufacturing, off-the-shelf NK cell products can be manufactured in advance and stockpiled. This provides the significant advantage of allowing patients to receive treatment quickly when needed, reducing waiting times and enabling rapid response for a greater number of patients.
Background & Context
While CAR-T cell therapies have shown remarkable success against hematological malignancies, high costs and manufacturing complexity remain barriers to their widespread adoption. Improved CAR-T cell therapies, such as dual antigen CAR-T, and readily available off-the-shelf NK cell therapies are key approaches to overcome these challenges and enhance treatment accessibility. NTHRYS’s achievements are crucial for accelerating the commercialization of these next-generation cell therapies and making them available to a broader patient population. Specifically, cost reduction and establishment of supply systems are indispensable for the expansion of the cell therapy market.
Strategic Significance & Outlook
NTHRYS’s cost reduction in dual antigen CAR-T manufacturing and the provision of off-the-shelf NK cell expansion services are poised to significantly accelerate the clinical application of immunotherapy for hematological malignancies. It is expected that cell therapy products utilizing these technologies will establish efficacy and safety in clinical trials and gain regulatory approval, allowing more patients to access innovative treatments. NTHRYS aims to continue innovating in cell therapy manufacturing processes, delivering high-quality, cost-effective cell therapy products to patients worldwide, further driving the paradigm shift in cancer treatment.
Source: https://nthrys.com/home/pdfs/projects/immunology–immunotherapy-for-hematological-malignancies.pdf
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments